These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

800 related items for PubMed ID: 27358067

  • 1. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
    Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS.
    Alzheimers Res Ther; 2016 Jun 30; 8():25. PubMed ID: 27358067
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 30; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 3. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.
    J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875
    [Abstract] [Full Text] [Related]

  • 4. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
    Geijselaers SLC, Aalten P, Ramakers IHGB, De Deyn PP, Heijboer AC, Koek HL, OldeRikkert MGM, Papma JM, Reesink FE, Smits LL, Stehouwer CDA, Teunissen CE, Verhey FRJ, van der Flier WM, Biessels GJ, Parelsnoer Institute Neurodegenerative Diseases study group.
    J Alzheimers Dis; 2018 Jul 29; 61(1):309-320. PubMed ID: 29154275
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R, Insel PS, Skillbäck T, Olsson B, Landén M, Frisoni GB, Herukka SK, Hampel H, Wallin A, Minthon L, Hansson O, Blennow K, Mattsson N, Zetterberg H.
    Alzheimers Res Ther; 2017 Oct 23; 9(1):87. PubMed ID: 29061195
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H, Tesseur I, Pemberton D, Van Der Ark P, Timmers M, Slemmon R, Janssens L, Streffer J, Van Nueten L, Bottelbergs A, Rauramaa T, Koivisto AM, Herukka SK, Korhonen VE, Junkkari A, Hiltunen M, Engelborghs S, Blennow K, Zetterberg H, Kolb HC, Leinonen V.
    J Alzheimers Dis; 2021 Oct 23; 80(4):1629-1642. PubMed ID: 33720890
    [Abstract] [Full Text] [Related]

  • 9. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
    Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ.
    Biol Psychiatry; 2008 Mar 15; 63(6):609-18. PubMed ID: 17720148
    [Abstract] [Full Text] [Related]

  • 10. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
    Reijs BLR, Ramakers IHGB, Elias-Sonnenschein L, Teunissen CE, Koel-Simmelink M, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Johannsen P, Vanderstichele H, Verhey F, Devanand DP, Visser PJ.
    J Alzheimers Dis; 2017 Mar 15; 60(3):1025-1034. PubMed ID: 28984603
    [Abstract] [Full Text] [Related]

  • 11. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.
    Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund LO, Salem N, Palmblad J.
    J Intern Med; 2014 Apr 15; 275(4):428-36. PubMed ID: 24410954
    [Abstract] [Full Text] [Related]

  • 12. CSF ApoE predicts clinical progression in nondemented APOEε4 carriers.
    van Harten AC, Jongbloed W, Teunissen CE, Scheltens P, Veerhuis R, van der Flier WM.
    Neurobiol Aging; 2017 Sep 15; 57():186-194. PubMed ID: 28571653
    [Abstract] [Full Text] [Related]

  • 13. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype.
    Babapour Mofrad R, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, Teunissen CE.
    Neurology; 2020 Oct 27; 95(17):e2378-e2388. PubMed ID: 32788242
    [Abstract] [Full Text] [Related]

  • 14. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.
    Bejanin A, Iulita MF, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, Fernandez S, Altuna M, Pegueroles J, Montal V, Valldeneu S, Giménez S, González-Ortiz S, Muñoz L, Padilla C, Aranha MR, Estellés T, Illán-Gala I, Belbin O, Camacho V, Wilson LR, Annus T, Osorio RS, Videla S, Lehmann S, Holland AJ, Zetterberg H, Blennow K, Alcolea D, Clarimon J, Zaman SH, Blesa R, Lleó A, Fortea J.
    JAMA Neurol; 2021 Aug 01; 78(8):937-947. PubMed ID: 34228042
    [Abstract] [Full Text] [Related]

  • 15. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ, Almeida MR, Ribeiro MH, Durães J, Tábuas-Pereira M, Pinheiro AC, Pascoal R, Santana I, Baldeiras I.
    Neurosci Lett; 2017 Feb 22; 641():101-106. PubMed ID: 28108398
    [Abstract] [Full Text] [Related]

  • 16. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K, Kern S, Zettergren A, Börjesson-Hansson A, Zetterberg H, Skoog I, Blennow K.
    Transl Psychiatry; 2017 Jan 10; 7(1):e995. PubMed ID: 28072416
    [Abstract] [Full Text] [Related]

  • 17. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando SB, Lauridsen C, Berge G, Grøntvedt GR, Bråthen G, White LR, Kultima K, Nielsen HM.
    Alzheimers Res Ther; 2022 Aug 24; 14(1):115. PubMed ID: 36002891
    [Abstract] [Full Text] [Related]

  • 18. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.
    Tapiola T, Pirttilä T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H.
    Neurobiol Aging; 2000 Aug 24; 21(5):735-40. PubMed ID: 11016543
    [Abstract] [Full Text] [Related]

  • 19. CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.
    Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H.
    Mol Psychiatry; 2014 Feb 24; 19(2):148-9. PubMed ID: 23419830
    [No Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.